Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

Innovative medicine production site inaugurated in France

16
SHARES

Sanofi’s novel manufacturing unit in France shortens production timelines and enables rapid changes in production capacities for medicines such as biologics and vaccines.

Sanofi Modulus

Credit: ArDanMe / Shutterstock.com

Sanofi has inaugurated a new production unit in France which utilises a world-first modular concept. The site, Modulus, located in Neuville-sur-Saône (Rhône-Alpes), is supported by an investment of nearly €500 million and will produce Sanofi’s next vaccines and biologic drugs.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

Modulus can adapt to manufacture up to four vaccines simultaneously. Notably, reconfiguration of the technological platform (live attenuated viral vaccines, recombinant protein or messenger RNA vaccines, as well as treatments derived from biotechnologies such as enzymes or monoclonal antibodies) takes a few days or weeks.

This is much shorter compared to the several months or years required in traditional industrial factories. Conventional sites have dedicated buildings for individual technologies or products, preventing rapid changes in production capacities, eg, integrating the arrival of a new drug or ramping up production of a vaccine in the event of a pandemic, Sanofi noted.

About Modulus

The 24,000m2 Modulus building contains “the equivalent of 34 standardised mini-factories, equipped with interconnected equipment, modular according to the required technology, in order to configure the production line corresponding to the needs of the moment”, Sanofi explained.

A manufacturing revolution

Modulus is not just a new, more modern, ecological and connected factory, but a revolution in the way we will manufacture vaccines and biomedicines in the coming decades”

Modulus is “not just a new, more modern, ecological and connected factory, but a revolution in the way we will manufacture vaccines and biomedicines in the coming decades. We have reinvented everything, from the design of the building to the way we collaborated with health authorities, to imagine a factory that will be best able to meet the health challenges of patients in France and around the world,” Sanofi’s CEO Paul Hudson shared.

Furthermore, the site will enable 200 new high value-added jobs to be created within the Neuville-sur-Saône site, Sanofi confirmed.

Inauguration of the plant follows several months after the company announced a major investment in its biologic production at the Vitry-sur-Seine site.

Sanofi anticipated that Modulus will be operational by the end of next year.

Share via
Share via